UCB has agreed to sell its UCB business and affiliates in selected emerging markets to GlaxoSmithKline for $670 million in cash. The transaction is expected to close in 1Q09. The commercial operations and product distribution rights acquired by GSK represents approximately 3-4% of UCB’s 2008 expected revenue of approximately $4.3 billion. The agreement includes more than 50 UCB operations in the Far East, Middle East, Latin America and Africa, and covers all currently marketed UCB produ...